Formoterol hemifumarate

• Supplier: R&D Systems
• Catalog: 1448
• Prices: $139.00, $585.00
• Sizes: 10 mg, 50 mg
• Cas Number: 43229-80-7
• Chemical Name: (±)-(R,R)-N-[2-Hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamidehemifumarate
• Formula: C19H24N2O4.½C4H4O4
• Molecular Weight: 402.45
• Purity: >99%

Product References

beta2-adrenoreceptor Inverse Agonist Down-regulates Muscarine Cholinergic - beta2-adrenoreceptor Inverse Agonist Down-regulates Muscarine Cholinergic

Luo J, Liu YH, Luo W, Luo Z, Liu CT. Sci Rep. 2017 Jan 4;7:39905.

beta2-adrenoreceptor stimulation dampens the LPS-induced M1 polarization in pig - beta2-adrenoreceptor stimulation dampens the LPS-induced M1 polarization in pig

Bacou E, Haurogne K, Allard M, Mignot G, Bach JM, Herve J, Lieubeau B. Dev Comp Immunol. 2017 Nov;76:169-176.

beta2-Adrenergic Receptor Antagonism Attenuates CNV Through Inhibition of VEGF - beta2-Adrenergic Receptor Antagonism Attenuates CNV Through Inhibition of VEGF

Lavine JA, Farnoodian M, Wang S, Darjatmoko SR, Wright LS, Gamm DM, Ip MS, Sorenson CM, Sheibani N. Invest Ophthalmol Vis Sci. 2017 Jan 1;58(1):299-308.

A long-acting beta2-adrenergic agonist increases the expression of muscarine - A long-acting beta2-adrenergic agonist increases the expression of muscarine

Liu YH, Wu SZ, Wang G, Huang NW, Liu CT. Mol Med Rep. 2015 Jun;11(6):4121-8.

Attenuation of choroidal neovascularization by beta(2)-adrenoreceptor antagonism. - Attenuation of choroidal neovascularization by beta(2)-adrenoreceptor antagonism.

Lavine JA, Sang Y, Wang S, Ip MS, Sheibani N. JAMA Ophthalmol. 2013 Mar;131(3):376-82.

Ectopic activity in the rat pulmonary vein can arise from simultaneous activation - Ectopic activity in the rat pulmonary vein can arise from simultaneous activation

Maupoil V, Bronquard C, Freslon JL, Cosnay P, Findlay I. Br J Pharmacol. 2007 Apr;150(7):899-905. Epub 2007 Feb 26.

Expression of inwardly rectifying potassium channels (GIRKs) and beta-adrenergic - Expression of inwardly rectifying potassium channels (GIRKs) and beta-adrenergic

Plummer HK 3rd, Yu Q, Cakir Y, Schuller HM. BMC Cancer. 2004 Dec 16;4:93.